CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 167 enrolled
Drug / intervention
Oral Tranexamic Acid +1 moredrug
Likely dose
Oral Tranexamic Acid 1950mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02233101
NCT02233101N/ACompleted
CompareCT.gov

Oral vs. Intravenous TXA Study Proposal: TJA

Rush University Medical Center·interventional·Posted Sep 8, 2014·Updated Nov 28, 2017

In Brief

A clinical study evaluating Oral Tranexamic Acid and Intravenous Tranexamic Acid for Blood Loss After Primary Total Joint Arthroplasty and Need for Blood Transfusion After Total Joint Arthroplasty. Completed, enrolled 167 participants across 1 site.

Detailed Summary

Purpose: Examine oral and intravenous Tranexamic Acid (TXA) to determine whether or not the different routes of drug administration are equivalent in terms of post-operative reduction in hemoglobin, number of transfusions, and post-operative blood loss following TJA surgery. Hypothesis: Oral and intravenous TXA are equivalent routes of drug administration.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBlood Loss After Primary Total Joint Arthroplasty, Need for Blood Transfusion After Total Joint Arthroplasty
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 8, 2014
Enrollment StartJun 1, 2014
Primary CompletionAug 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 11.8 years ago

Interventions

Oral Tranexamic Aciddrug

patients will receive 1950mg of oral prior to surgery to help reduce blood loss during total joint replacement

Intravenous Tranexamic Aciddrug

Patients will receive 1950mg of intravenous Tranexamic Acid prior to total joint arthroplasty and blood loss or need for transfusion within 24 hours post operative